Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 6
2005 6
2006 4
2007 5
2008 2
2009 4
2010 8
2011 5
2012 2
2013 1
2015 4
2016 3
2017 1
2018 3
2019 1
2020 1
2021 1
2022 6
2023 6
2024 3
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P; PAOLA-1/ENGOT-ov25 investigators. Ray-Coquard I, et al. Among authors: denschlag d. Ann Oncol. 2023 Aug;34(8):681-692. doi: 10.1016/j.annonc.2023.05.005. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211045 Free article. Clinical Trial.
Uterine Adenosarcoma.
Ulrich UA, Denschlag D. Ulrich UA, et al. Among authors: denschlag d. Oncol Res Treat. 2018;41(11):693-696. doi: 10.1159/000494067. Epub 2018 Oct 17. Oncol Res Treat. 2018. PMID: 30326467 Review.
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, Denschlag D, Myers T, Thijs AM, Pennington KP, Gilbert L, Fleming E, Zub O, Landrum LM, Ataseven B, Gogoi R, Podzielinski I, Cloven N, Monk BJ, Sharma S, Herzog TJ, Stuckey A, Pothuri B, Secord AA, Chase D, Vincent V, Meyers O, Garside J, Mirza MR, Black D. Valabrega G, et al. Among authors: denschlag d. Int J Gynecol Cancer. 2025 Jun;35(6):101852. doi: 10.1136/ijgc-2024-005484. Epub 2025 Apr 19. Int J Gynecol Cancer. 2025. PMID: 39322611 Free article. Clinical Trial.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Among authors: denschlag d. Ann Oncol. 2025 Feb;36(2):185-196. doi: 10.1016/j.annonc.2024.10.828. Epub 2024 Nov 9. Ann Oncol. 2025. PMID: 39528049 Free article. Clinical Trial.
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).
Wallwiener M, Battista MJ, Burandt EC, Cremer W, Egerer G, Fehr MK, Follmann M, Gass P, Haase H, Harter P, Heitz F, Hettmer S, Horn LC, Juhasz-Böss I, Kast K, Köhler G, Kröncke T, Lindel K, Mustea A, Novotny JP, Petru E, Reichardt P, Rhiem K, Strauß HG, Tempfer C, Thiel FC, Ulrich UA, Vogl T, Vordermark D, Denschlag D. Wallwiener M, et al. Among authors: denschlag d. Geburtshilfe Frauenheilkd. 2025 Apr 3;85(4):378-394. doi: 10.1055/a-2496-2591. eCollection 2025 Apr. Geburtshilfe Frauenheilkd. 2025. PMID: 40195954 Free PMC article.
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.
Denschlag D, Czogalla B, Heitz F, Kerkmann M, Fangmann LC, Klecker PH, Stuebs FA, Wölber L, Radosa J, Lodde PC, Seitz S, George C, Mach P, Fink A, Bokhua D, deGregorio N, Lampe B, Hemptenmacher F, Friebe V, Fleisch M, Wimberger P, Jaeger A, Schnelzer A, Mittelstadt S, Ratiu D, Eichbaum M, Haus A, Kalder M, Ataseven B, Schröder W, Bronger H, Kosse J, Ulrich UA, Elser G, Harter P. Denschlag D, et al. Geburtshilfe Frauenheilkd. 2025 May 15;85(5):520-532. doi: 10.1055/a-2520-5736. eCollection 2025 May. Geburtshilfe Frauenheilkd. 2025. PMID: 40386500 Free PMC article.
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study.
Jaeger A, Hampl M, Prieske K, Eulenburg C, Reichenbach J, Klapdor R, Heublein S, Schochter F, Gaß P, Rohner A, Canzler U, Becker S, Bommert M, Bauerschlag D, Denecke A, Hanker L, Runnebaum I, Forner DM, Klar M, Schwab R, Koepke M, Kalder M, Hantschmann P, Ratiu D, Denschlag D, Schroeder W, Tuschy B, Baumann K, Mustea A, Soergel P, Bronger H, Bauerschmitz G, Kosse J, Koch MC, Ignatov A, Sehouli J, Dannecker C, Schmalfeldt B, Mahner S, Woelber L. Jaeger A, et al. Among authors: denschlag d. Gynecol Oncol. 2025 Sep;200:8-13. doi: 10.1016/j.ygyno.2025.07.003. Epub 2025 Jul 16. Gynecol Oncol. 2025. PMID: 40669125
[The corpus luteum].
Denschlag D, Keck C. Denschlag D, et al. Ther Umsch. 2002 Apr;59(4):159-62. doi: 10.1024/0040-5930.59.4.159. Ther Umsch. 2002. PMID: 12018033 German.
70 results